Resistant Hypertension Research Is Running on Blurred Phenotypes
Resistant hypertension remains one of the most inconsistently defined syndromes in cardiovascular medicine. The condition carries a high burden of major adverse cardiovascular events, yet the evidence base is weakened by a problem that starts before any analysis begins: too many datasets cannot reliably separate true treatment resistance from pseudo-resistance.
In clinical practice, that distinction determines whether a patient needs a different regimen, better blood pressure measurement, closer adherence support, or a deeper secondary workup. In research, it determines whether a genetic signal is real or merely buried inside a mixed population of treated, undertreated, and intermittently treated patients.
The article argues that resistant hypertension is often treated as if it were a single disease entity when it is really a composite of several clinical states. White-coat effect, measurement error, poor medication adherence, incomplete prescribing records, and dose uncertainty all collapse into the same label when the underlying data are thin. The result is a phenotype that looks tidy in an algorithm but is biologically noisy at the bedside.
Adherence Gaps Are Reclassifying Patients in Plain Sight
The most disruptive source of misclassification is non-adherence. Resistant hypertension is usually defined by blood pressure above target despite the use of three or more antihypertensive agents, but that definition assumes the prescribed drugs are actually taken as intended. In routine care, especially where pill burden is high and single-pill combinations are limited, that assumption often fails.
Reported adherence to antihypertensive therapy is only 27% to 40%, and the article treats that figure as a central obstacle rather than a side issue. Once adherence becomes uncertain, the label of resistant hypertension loses precision. Some patients are genuinely resistant because their vascular biology, renal sodium handling, or neurohormonal drive remains uncontrolled despite appropriate therapy. Others simply look resistant because tablets are not being taken, prescriptions are not being refilled, or the medication list does not reflect true exposure.
This is not a semantic problem. It changes the entire downstream interpretation of risk, treatment response, and mechanism. A patient who misses doses intermittently may appear to have refractory hypertension, yet the pathophysiology is closer to inconsistent pharmacologic exposure than to true pharmacologic failure.
Biobanks Are Powerful, but Their Medication Fields Are Too Thin
Population-scale biobanks have transformed cardiovascular genetics by supplying the numbers needed to detect small effects across common blood pressure traits. Their strength lies in breadth. Their weakness lies in depth.
Prescribing data in these resources are often incomplete or inconsistently coded. Some records capture issuance but not dose, duration, refill history, or whether the prescription translated into actual medication possession. Dispensing data and objective adherence measures are rarely linked. Self-report, when used as a substitute, is vulnerable to recall bias and social desirability effects, which systematically push non-adherence out of view.
The article also identifies a coding problem that has slowed progress for years. Resistant hypertension lacked a dedicated ICD-10 code for a long time, and the newer RH-specific code introduced in 2023 is still absent from UK primary care classifications. Much of the available biobank material predates even that limited standardization, forcing investigators to infer cases from baseline blood pressure values, self-reported medication use, and ad hoc algorithms rather than clinician-assigned diagnoses.
A phenotype built from incomplete medication exposure data is not just noisy; it is structurally biased toward misclassification. In resistant hypertension, that means pseudo-resistance is folded into the case definition and true resistance is diluted.
Misclassification Weakens Genetic Discovery and Pharmacogenomics
The consequences for genetics are immediate. Genome-wide studies depend on clean case definitions, and pharmacogenomic studies depend on both genotype and treatment exposure being measured with reasonable accuracy. If the phenotype is blurred, the signal-to-noise ratio collapses.
This is especially damaging for drug-response research. A variant that genuinely alters response to a diuretic, calcium-channel blocker, or renin-angiotensin inhibitor can disappear into a dataset where some participants never took the drug consistently, some never filled it, and some were not truly resistant in the first place. The wrong inference is easy to make: a biologically meaningful association may look absent simply because the exposure definition is wrong.
The article points to prior genome-wide studies of resistant hypertension that already acknowledged missing white-coat status, adherence data, and dose information as major limitations. Those gaps are not minor technical footnotes. They can flatten genetic associations, lower power, and obscure mechanisms that would otherwise be detectable in a cleaner cohort.
A variant cannot modify treatment response if treatment response itself is mismeasured.
Proxy Strategies Can Help, but They Do Not Solve the Problem
The article does not argue that large datasets are unusable. It argues that they need more disciplined proxy methods until richer medication data become available.
Several pragmatic approaches are described. Some studies have used prescription regularity, requiring evidence of repeat prescribing at fixed intervals to approximate sustained treatment. Others have used monthly primary care prescribing patterns as a marker of medication availability. Look-back windows can help identify contemporaneous therapy rather than remote historical prescriptions, and those windows may be randomized or varied to reduce bias from seasonality in prescribing or recording.
These methods are useful because they preserve sample size while imposing some discipline on phenotype definition. But each proxy remains an approximation. A filled prescription is not proof of ingestion. A repeated script is not proof of physiologic exposure. A clean medication record can still miss tablets skipped, shared, discarded, or taken irregularly.
Even so, the article makes clear that conservative proxy strategies are preferable to uncritical case labeling. Better to define fewer participants with higher confidence than to inflate the case pool with mixed biology and call it precision medicine.
Resistant Hypertension Needs Better Data Before It Can Yield Better Biology
The central message is straightforward: resistant hypertension research is constrained less by lack of ambition than by lack of exposure fidelity. Without consistent prescription coding, adherence measurement, dispensing linkage, and diagnostic standardization, the field will continue to confuse pseudo-resistance with true resistance.
For clinicians, the bedside implication is immediate. When blood pressure remains above target on three or more agents, the next question is not only which medication to add, but whether the patient is actually receiving and taking the current regimen. That question is fundamental to diagnosis, not an afterthought.
For researchers, the bar is higher. Genetic studies, pharmacoepidemiology, and treatment-response analyses will remain vulnerable until medication exposure is measured with greater specificity than a single prescription line or a self-reported pill list can provide. The article closes with the practical reality that resistant hypertension cannot be mapped accurately if the underlying medication history is incomplete, and any future discovery effort will inherit those blind spots unless the data infrastructure changes.